There is a disease epidemic unfolding across India’s cities right now, and most of its victims have no idea they are affected. It produces no obvious symptoms in its early stages. It doesn’t show up in routine blood work until significant damage has already occurred. And it is directly, causally linked to something that a standard health check cannot measure: the amount of fat deposited around your internal organs.<\/p>\n
Non-Alcoholic Fatty Liver Disease (NAFLD)<\/strong> \u2014 the accumulation of fat in the liver of people who drink little or no alcohol \u2014 now affects an estimated 30\u201340% of urban Indian adults<\/strong>. In some city-specific studies, the prevalence reaches 46%. With India’s urban population exceeding 500 million and growing, NAFLD may already be the country’s most common chronic liver condition, surpassing viral hepatitis in absolute numbers.<\/p>\n This is not a disease that happens to people who make obviously bad choices. It is happening to people who appear healthy, who have never touched alcohol, who visit their doctors regularly \u2014 and whose standard blood tests show nothing alarming until the disease is well advanced. Understanding NAFLD requires understanding visceral fat, and understanding visceral fat requires measuring body composition.<\/p>\n The liver is the body’s primary metabolic processing center. It handles glucose storage and release, fat metabolism, protein synthesis, detoxification, and hundreds of other critical functions. Under normal circumstances, the liver contains only a small amount of fat \u2014 less than 5% of its weight.<\/p>\n NAFLD is defined as fat accumulation exceeding 5% of liver weight in the absence of significant alcohol consumption. It exists on a spectrum:<\/p>\n The alarming reality is that India is seeing NAFLD at both ends of the progression simultaneously: enormous numbers of cases in the early, reversible stages \u2014 and a rising incidence of advanced fibrosis and cirrhosis in people who never drank alcohol and never received an NAFLD diagnosis until liver function was seriously compromised.<\/p>\n This is the question that confuses patients most. “I don’t drink \u2014 how can I have fatty liver?”<\/p>\n The answer lies in understanding that the liver doesn’t particularly care whether the excess metabolic load comes from alcohol or from other sources. What drives NAFLD is not alcohol \u2014 it is metabolic dysfunction, primarily:<\/p>\n Fructose is metabolized almost exclusively in the liver. When fructose consumption exceeds the liver’s processing capacity, the excess is converted directly to triglycerides and stored as hepatic fat. The modern Indian urban diet is remarkably high in fructose sources: soft drinks, fruit juices, mithai, biscuits, packaged snacks, and the sucrose in chai. This is the dietary driver that most closely mimics alcohol’s effect on liver fat accumulation \u2014 without a single drink consumed.<\/p>\n White rice, maida-based bread, and refined grains spike blood glucose rapidly. The resulting insulin response drives de novo lipogenesis (fat creation from carbohydrates) in the liver. Indian dietary patterns \u2014 rice at every meal, roti made from refined atta, deep-fried snacks \u2014 create the metabolic conditions for hepatic fat accumulation in people who eat what would conventionally be considered a “normal” Indian diet.<\/p>\n Urbanization in India has been accompanied by a dramatic reduction in physical activity. The generation that walked to school, played outdoors, and worked manual labor jobs has been replaced by one that commutes in autos and ride-shares, sits at desks for 8\u201310 hours, and exercises rarely if at all. Without physical activity to consume glucose and triglycerides, metabolic byproducts accumulate \u2014 primarily in the liver and in visceral fat.<\/p>\n Indians develop NAFLD at lower levels of obesity than Western populations. Genetic variants affecting lipid metabolism (PNPLA3, TM6SF2, MBOAT7 polymorphisms) are more prevalent in South Asian populations and increase hepatic fat accumulation at lower visceral fat thresholds. This means an Indian person can develop clinically significant fatty liver at a body weight and visceral fat level that would pose little hepatic risk in a person of European ancestry.<\/p>\n Of all the risk factors for NAFLD, visceral fat is the most important and the most directly causal. This is not a correlation \u2014 it is a mechanism.<\/p>\n Visceral fat \u2014 the fat stored around the liver, intestines, pancreas, and other intra-abdominal organs \u2014 is metabolically distinct from subcutaneous fat. Unlike subcutaneous fat, which releases fatty acids into the systemic circulation, visceral fat drains directly into the portal vein<\/strong> \u2014 the blood vessel that feeds the liver. This means the liver receives a continuous, disproportionate flood of free fatty acids from visceral fat, far beyond what it can process and oxidize efficiently.<\/p>\n The result: the liver converts the excess fatty acids into triglycerides and stores them in hepatocytes (liver cells). Over time, this accumulation triggers oxidative stress, inflammation, and the progression from simple steatosis toward NASH.<\/p>\n This is why NAFLD and visceral fat are so tightly correlated. It is also why reducing visceral fat is the single most effective intervention for reversing early-stage NAFLD \u2014 more effective than any current medication (there is, as of 2026, no FDA-approved pharmacological treatment for NAFLD).<\/p>\n InBody’s Visceral Fat Area measurement \u2014 derived from bioelectrical impedance analysis \u2014 gives a precise, validated estimate of the fat surrounding the abdominal organs. Research using InBody analysis alongside liver ultrasound and CT imaging has established important thresholds:<\/p>\n For Indian populations specifically, given their lower fat threshold for metabolic complications, a VFA above 85\u201390 cm\u00b2 should trigger concern and investigation. This is a data point that an InBody measurement can deliver in minutes \u2014 information that correlates directly with what an abdominal ultrasound would show, but is accessible, affordable, and repeatable for longitudinal monitoring.<\/p>\n One of the more nuanced metrics InBody provides is the ratio of Extracellular Water to Total Body Water (ECW\/TBW). Under healthy conditions, this ratio sits at approximately 0.360\u20130.375. As chronic inflammation develops \u2014 whether from NAFLD, metabolic syndrome, or autoimmune conditions \u2014 the body shifts fluid from intracellular to extracellular compartments, and ECW\/TBW rises.<\/p>\n In patients with established NAFLD, particularly those progressing toward NASH, elevated ECW\/TBW is a recognizable pattern. It reflects not just liver inflammation but systemic low-grade inflammation that accompanies metabolic dysfunction. Tracking ECW\/TBW over time gives a proxy indicator of whether the inflammatory burden associated with NAFLD is improving or worsening \u2014 complementing, though not replacing, formal hepatic imaging.<\/p>\n The standard liver function tests most Indians receive during health checkups \u2014 ALT, AST, GGT, bilirubin \u2014 are surprisingly poor at detecting early NAFLD. Liver enzymes can remain completely normal even when 20\u201330% of liver tissue is fatty. They begin to rise only when significant inflammation or cell death is occurring (NASH stage or beyond).<\/p>\n Similarly, abdominal ultrasound \u2014 the most common imaging tool for liver assessment in India \u2014 reliably detects fatty liver only when more than 20\u201330% of hepatocytes are affected. By then, the disease is no longer in its earliest, most reversible stage.<\/p>\n This diagnostic gap means that visceral fat assessment through body composition analysis is not just complementary to standard care \u2014 for many Indian adults in the pre-symptomatic phase, it may be the only accessible indicator that something is wrong before significant hepatic damage accumulates.<\/p>\n Patients who successfully reverse early NAFLD through lifestyle intervention often experience a confusing phenomenon: the scale barely moves, but imaging shows dramatic improvement in hepatic fat. This is because the interventions that most effectively target liver fat \u2014 reducing refined carbohydrates, increasing exercise, building muscle \u2014 also improve body composition in ways that can mask fat loss on the scale.<\/p>\n When visceral and hepatic fat decreases while skeletal muscle mass increases (as happens with resistance training combined with caloric control), total body weight may remain stable or change only modestly. But the InBody data tells the real story: VFA dropping from 130 cm\u00b2 to 85 cm\u00b2 represents a profound, clinically meaningful improvement in liver fat and metabolic risk \u2014 even if the person weighs the same.<\/p>\n This is why physicians at liver clinics in India increasingly use body composition analysis as a monitoring tool for NAFLD management. It captures the changes that matter \u2014 and that the scale misses entirely.<\/p>\n Soft drinks, packaged fruit juices, sugary chai, energy drinks, and processed sweetened beverages are the fastest route to hepatic fat accumulation. Eliminating liquid sugar is the highest-yield dietary intervention for NAFLD and should be the first, non-negotiable step. Water, plain chai with minimal sugar, buttermilk, and coconut water (in moderation) are the replacements.<\/p>\n Replace white rice and maida with millets (ragi, jowar, bajra), whole wheat, oats, and legumes. These reduce the glycemic impact of meals, lower the de novo lipogenesis load on the liver, and increase dietary fiber which beneficially affects gut microbiome and liver fat metabolism.<\/p>\n Aerobic exercise directly reduces hepatic fat independently of weight loss. 150 minutes per week of moderate-intensity aerobic exercise (brisk walking, cycling, swimming) produces measurable reductions in liver fat in 8\u201312 weeks. Adding resistance training amplifies the benefit by reducing visceral fat more effectively than aerobic exercise alone and by building skeletal muscle mass, which increases resting metabolic rate and glucose disposal capacity.<\/p>\n Multiple large studies have confirmed that coffee consumption (2\u20133 cups daily, without excessive sugar) is protective against NAFLD progression. Coffee appears to inhibit fibrosis pathways in the liver. This is one of the few dietary interventions with consistent evidence for direct liver protection.<\/p>\n DHA and EPA (found in fatty fish, algal oil supplements, and to a lesser extent in flaxseed as ALA) reduce hepatic triglyceride synthesis and have anti-inflammatory effects in liver tissue. For Indian vegetarians, supplementation with algal DHA\/EPA is a practical approach. Walnuts and flaxseeds provide ALA but with limited conversion efficiency.<\/p>\n Before closing, it is essential to note that NAFLD is no longer exclusively an adult disease in India. With the explosive rise in childhood obesity, sedentary screen time, and ultra-processed food consumption, NAFLD is increasingly being detected in Indian children and adolescents \u2014 some as young as 8\u201310 years old. Paediatric endocrinologists at major Indian hospitals are now routinely finding NAFLD on ultrasound in overweight children who are brought in for assessment of other metabolic concerns.<\/p>\n Body composition assessment in children is not just valid \u2014 with appropriate reference ranges (as InBody provides for different age groups), it is a powerful screening tool for identifying paediatric visceral adiposity before metabolic complications manifest.<\/p>\n NAFLD is a stealth disease. It builds silently over years, behind a facade of normal blood tests and tolerable waistline measurements, until the liver’s reserve is sufficiently depleted that symptoms emerge. By that point, reversal is harder, and the risk of serious outcomes \u2014 cirrhosis, liver failure, liver cancer \u2014 is real.<\/p>\n The most powerful thing you can do is get ahead of it. An InBody body composition analysis gives you your Visceral Fat Area, the primary predictor of hepatic fat accumulation, alongside a complete picture of your body’s muscle-to-fat ratio and inflammatory markers. It takes five minutes. It is available at hospitals, clinics, and fitness centers across India.<\/p>\nWhat Is NAFLD and Why Is It India’s Silent Epidemic?<\/h2>\n
\n
Why Alcohol-Abstaining Indians Still Develop Fatty Liver<\/h2>\n
Excess Fructose and Refined Carbohydrates<\/h3>\n
Refined Carbohydrate Overload<\/h3>\n
The Sedentary Transition<\/h3>\n
South Asian Genetic Susceptibility<\/h3>\n
The Direct Causal Link Between Visceral Fat and Liver Fat<\/h2>\n
The VFA Threshold That Predicts Liver Fat Accumulation<\/h2>\n
\n
The ECW\/TBW Ratio as an Early Marker of Liver Inflammation<\/h2>\n
Why Standard Blood Tests Miss Early NAFLD<\/h2>\n
Why the Scale Doesn’t Show NAFLD Progress<\/h2>\n
The Liver-Protective Intervention Protocol<\/h2>\n
Priority 1: Eliminate Liquid Sugar<\/h3>\n
Priority 2: Reduce Refined Carbohydrates<\/h3>\n
Priority 3: Exercise \u2014 Both Aerobic and Resistance<\/h3>\n
Priority 4: Coffee \u2014 Genuinely Hepatoprotective<\/h3>\n
Priority 5: Omega-3 Fatty Acids<\/h3>\n
NAFLD in Children: India’s Emerging Paediatric Crisis<\/h2>\n
Know Your Visceral Fat Number Before It’s Too Late<\/h2>\n